Gout
📧 Sign up to get email alerts when something new happens for Gout.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2012-01-23Clinical Trial Update: Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout [Phase 2]
A Phase 2 study evaluating the urate-lowering activity and safety of oral BCX4208 in gout has been completed.
-
CLINICAL_TRIALS trial_result · 2012-01-23Clinical Trial Update: Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout [Phase 2]
Phase 2 study evaluating the uric acid‑lowering activity, safety, and pharmacokinetic interaction of oral BCX4208 with allopurinol in subjec…
-
CLINICAL_TRIALS trial_result · 2011-12-26Clinical Trial Update: Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study. [Phase 3]
Phase 3 trial update showing results of canakinumab for acute gout flares and prevention of future flares in NSAID/colchicine-intolerant pat…
-
CLINICAL_TRIALS trial_result · 2011-12-02Clinical Trial Update: Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout [Phase 3]
An open-label extension of a Phase 3 study of pegloticase (PEG-uricase) for symptomatic gout has completed, with results posted in 2011.
-
CLINICAL_TRIALS trial_result · 2011-11-18Clinical Trial Update: Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study [Phase 3]
Phase 3 trial update on canakinumab for acute gout flares and prevention in patients unable to use NSAIDs or colchicine, including a 12-week…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2011-11-08FDA Approved: NAPROXEN — Original Application (Aurobindo Pharma Limited)
The FDA approved Aurobindo Pharma Limited's original application for a generic naproxen product. Naproxen is a nonsteroidal anti-inflammator…
-
FDA approval · 2011-09-19FDA Approved: NAPROXEN — Original Application (Cipla USA Inc.)
FDA approves Cipla USA Inc.'s Naproxen under Original Application, making a generic naproxen product available. It is used to relieve pain a…
-
FDA approval · 2011-07-20FDA Approved: COLCRYS — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for COLCRYS (colchicine) from Takeda Pharmaceuticals America, Inc.
-
CLINICAL_TRIALS trial_result · 2011-06-28Clinical Trial Update: Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients [Phase 3]
Phase 3 re-exposure study of intravenous pegloticase in symptomatic gout patients has completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2011-05-16Clinical Trial Update: Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients [Phase 2]
A Phase 2 trial update describing targeted dose finding for canakinumab in acute gout patients who are refractory or contraindicated, with t…
-
CLINICAL_TRIALS trial_result · 2011-05-06Clinical Trial Update: A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study) [Phase 2]
Phase 2 study results evaluate canakinumab for preventing acute gout flares in patients starting allopurinol, with a long-term extension ass…
-
FDA approval · 2011-04-12FDA Approved: INDOMETHACIN — Original Application (XLCare Pharmaceuticals Inc.)
FDA approved the Indomethacin Original Application for XLCare Pharmaceuticals Inc., enabling a generic indomethacin product to reach the mar…
-
CLINICAL_TRIALS trial_result · 2011-03-08Clinical Trial Update: Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout [Phase 4]
A Phase 4 clinical trial update describing initiation of allopurinol at first medical contact for acute gout attacks; the study has complete…
-
CLINICAL_TRIALS trial_result · 2011-02-25Clinical Trial Update: Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout [Phase 3]
Phase 3 trial update reporting safety and efficacy results for PEG-uricase (pegloticase) in hyperuricemic patients with symptomatic gout; re…
-
FDA approval · 2011-01-28FDA Approved: ULORIC — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for ULORIC (febuxostat) submitted by Takeda Pharmaceuticals America, Inc. This notice indicates …
-
CLINICAL_TRIALS trial_result · 2011-01-06Clinical Trial Update: Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia [Phase 2]
A Phase 2 clinical trial evaluating tranilast alone or in combination with allopurinol in individuals with gout and hyperuricemia has comple…
-
CLINICAL_TRIALS trial_result · 2011-01-06Clinical Trial Update: Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia [Phase 2]
A Phase 2 clinical trial evaluating tranilast alone or in combination with febuxostat in patients with gout and hyperuricemia has completed.
-
CLINICAL_TRIALS trial_result · 2011-01-06Clinical Trial Update: Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO) [Phase 2]
Phase 2 trial evaluating tranilast in combination with allopurinol for moderate to severe gout with hyperuricemia has completed.
-
CLINICAL_TRIALS trial_result · 2010-12-03Clinical Trial Update: Uric Acid Study in Healthy Male Volunteers [Phase 1]
Phase 1 uric acid study in healthy male volunteers sponsored by AstraZeneca has completed; the study involved conditions including gout and …
-
FDA approval · 2010-10-19FDA Approved: KRYSTEXXA — Supplemental Application (Horizon Therapeutics USA, Inc.)
The FDA approves a supplemental application for KRYSTEXXA (pegloticase) submitted by Horizon Therapeutics USA, Inc.
-
FDA approval · 2010-09-14FDA Approved: KRYSTEXXA — Original Application (Horizon Therapeutics USA, Inc.)
FDA approves KRYSTEXXA (pegloticase) under the original Biologics License Application for adults with chronic gout refractory to conventiona…
-
FDA approval · 2010-08-12FDA Approved: NAPROXEN SODIUM — Supplemental Application (Bionpharma Inc.)
The FDA approved a supplemental application for Naproxen Sodium submitted by Bionpharma Inc.
-
FDA approval · 2010-04-29FDA Approved: COLCRYS — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for Colcrys (colchicine) submitted by Takeda Pharmaceuticals America, Inc.
-
CLINICAL_TRIALS trial_result · 2010-02-23Clinical Trial Update: Safety and Efficacy Study of Intravenous Uricase-PEG 20 [Phase 1]
This Phase 1 trial evaluates the safety and preliminary efficacy of intravenous Uricase-PEG 20 for treating gout and hyperuricemia.
-
CLINICAL_TRIALS trial_result · 2009-12-24Clinical Trial Update: Safety and Efficacy Study of Intramuscular Uricase-PEG 20 [Phase 1]
This update reports on a Phase 1 safety and efficacy study of intramuscular Uricase-PEG 20 for gout and hyperuricemia. The study assesses pr…